Matsuda Masaru sold $1.4M of ARQT

Matsuda Masaru (EVP, Chief Legal Officer) sold 41,219 shares of Arcutis Biotherapeutics, Inc. (ARQT) at an average of $34.24 ($31.86–$34.32, $1.41M total) across 2 trades over 2026-11-02 to 2026-11-04 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Matsuda Masaru
Published Nov 4, 2026, 11:38 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 4, 2026, 11:42 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ARQT
Bearish
medium confidence
Mentioned
$ARQT
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ARQTBearishLow
01

Why it matters

The disclosed sale may lead to short‑term price weakness, but the long‑term effect depends on subsequent company performance.

02

Market read

A modest insider sell that could cause short‑term pressure but is unlikely to move the broader market.

03

What to watch

The 10b5‑1 plan may have been set before any material news, limiting informational value.

Relevance 5/10Novelty 5/10Timing: after-hours filing

Background

Form 4 filings disclose insider transactions and are primary sources for such events.

Company-level read

Ticker impact

$ARQTBearishMedium confidence
Context

SEC Form 4 shows EVP Matsuda Masaru sold 41,219 shares for $1.41M via a 10b5‑1 plan.

Expected impact

likely downward pressure as the market prices the insider sell.

Evidence & confidence

A C‑suite officer sold a sizable block at $34 per share, indicating possible valuation concerns.

Market effects

Minimal impact on the broader biotech sector.

None

Low

Counterpoint

The sale could be routine execution of a pre‑arranged plan, not a negative signal.

Key entities

  • Matsuda Masaru

    EVP, Chief Legal Officer of Arcutis Biotherapeutics.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ARQTHighAI 8/10

Arcutis reports trial data on infant eczema treatment candidate

Arcutis Biotherapeutics (ARQT) presented INTEGUMENT-INFANT trial data for ZORYVE cream 0.05% in treating infant atopic dermatitis. The study showed no serious adverse events, with 66.7% of infants reporting itch improvement within 4 hours. The cream is approved for children 2-5 years and is under FDA review for infants 3-24 months, with a decision expected by February 23, 2027.

$ARQTMed

Arcutis (ARQT) Q3 2026 Earnings Call Transcript

Arcutis Biotherapeutics (ARQT) reported Q3 2026 revenue of $143.9M, up 45% YoY, driven by ZORYVE franchise growth. Full-year revenue guidance raised to $535M-$545M. Net income was $8.8M, with cash and securities at $259.8M. The company plans to invest in commercial initiatives for 2027 growth, focusing on dermatology and primary care.

$ARQTMedAI 8/10

TD Cowen raises Arcutis stock price target on Zoryve momentum

TD Cowen raised its price target for Arcutis Biotherapeutics (ARQT) to $40 from $35, citing strong Zoryve sales of $144M and raised 2026 guidance. Revenue grew 11% quarter-over-quarter and 45% year-over-year, with a 91% gross profit margin. The stock trades near its 52-week high at $34.05. Arcutis reported Q3 2026 revenue of $143.9M, beating estimates, but missed profit expectations.